Download our whitepaper,
"Evolving Insights into Acute Pain: Diagnosis and Treatment"
What's Inside:
- Key FDA-Approved Pivotal Endpoints for Acute Pain Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for Acute Pain.
- Comprehensive Analysis of FDA-Approved Acute Pain Drugs.
- How Diagnostic Criteria for Acute Pain Have Evolved and Impact Research.
- Overcoming Common Pitfalls in Acute Pain Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
Acute Pain
Historically, acute pain was primarily viewed as a symptom of an underlying condition, with the focus on treating the cause rather than the pain itself.
The latter half of the 20th century saw further advancements in the understanding of pain mechanisms. Research into the neurobiology of pain revealed the complex interplay between the peripheral and central nervous systems, leading to the development of more targeted therapies. The recognition of the biopsychosocial model of pain emphasized the importance of psychological and social factors in pain perception and management.
iNGENū’s team of researchers and clinicians is dedicated to advancing acute pain research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by Acute Pain.
Poorly managed acute pain increases the likelihood of complications and prolonged hospital stays by
2-3
times
Over
50%
of emergency department patients with acute pain rate it as 7 or higher on a 10-point scale
Acute pain is the most common reason for emergency department visits, accounting for
45%
of all visits
Our clinical team has over
120
years of combined clinical trial experience